interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Lacosamide

Generic competition · all medicines · read 12 November 2026

Is there a generic of Lacosamide, and who makes it?

Lacosamide appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 28 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 12.1 and 13.4 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Lacosamide4 dosage-form groups in the Orange Book
28generic makers listed
  1. Lacosamide appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 28 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 12.1 and 13.4 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Four or more generic makers listed

Brand listed as marketed: Vimpat. 12 generic makers with 48 generic products listed as marketed; the first generic approval is dated 17 March 2022.

200520102015202020252030012brand 2008Alembic Pharmaceuticals Ltd, first approval 17 March 2022Glenmark Pharmaceuticals Ltd, first approval 17 March 2022Hetero Labs Ltd Unit V, first approval 17 March 2022Msn Laboratories Private Ltd, first approval 17 March 2022Regcon Holdings Llc, first approval 17 March 2022Sciegen Pharmaceuticals Inc, first approval 17 March 2022Sun Pharmaceutical Industries Ltd, first approval 17 March 2022Alkem Laboratories Ltd, first approval 31 March 2022Aurobindo Pharma Ltd, first approval 5 January 2023Pharmazone, first approval 2 April 2024Macleods Pharmaceuticals Ltd, first approval 24 May 2024Unichem Laboratories Ltd, first approval 4 September 2024data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Alembic Pharmaceuticals Ltd17 March 20224
Glenmark Pharmaceuticals Ltd17 March 20224
Hetero Labs Ltd Unit V17 March 20224
Msn Laboratories Private Ltd17 March 20224
Regcon Holdings Llc17 March 20224
Sciegen Pharmaceuticals Inc17 March 20224
Sun Pharmaceutical Industries Ltd17 March 20224
Alkem Laboratories Ltd31 March 20224
Aurobindo Pharma Ltd5 January 20234
Pharmazone2 April 20244
Macleods Pharmaceuticals Ltd24 May 20244
Unichem Laboratories Ltd4 September 20244

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Intravenous

Four or more generic makers listed

Brand listed as marketed: Vimpat. 14 generic makers with 14 generic products listed as marketed; the first generic approval is dated 7 April 2022.

200520102015202020252030014brand 2008Regcon Holdings Llc, first approval 7 April 2022Fresenius Kabi Usa Llc, first approval 3 May 2022Zydus Pharmaceuticals Usa Inc, first approval 29 June 2022Aspiro Pharma Ltd, first approval 14 September 2022Gland Pharma Ltd, first approval 19 September 2022Msn Laboratories Private Ltd, first approval 9 February 2023Apotex Inc, first approval 13 November 2023Hainan Poly Pharm Co Ltd, first approval 13 February 2024Dr Reddys Laboratories Ltd, first approval 25 March 2024Hikma Pharmaceuticals Usa Inc, first approval 5 April 2024Somerset Therapeutics Llc, first approval 9 October 2024Acella Pharmaceuticals Llc, first approval 14 November 2024Op Nanopharma Co Ltd Yunlin Plant, first approval 23 May 2025Glenmark Pharmaceuticals Inc Usa, first approval 21 January 2026data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Regcon Holdings Llc7 April 20221
Fresenius Kabi Usa Llc3 May 20221
Zydus Pharmaceuticals Usa Inc29 June 20221
Aspiro Pharma Ltd14 September 20221
Gland Pharma Ltd19 September 20221
Msn Laboratories Private Ltd9 February 20231
Apotex Inc13 November 20231
Hainan Poly Pharm Co Ltd13 February 20241
Dr Reddys Laboratories Ltd25 March 20241
Hikma Pharmaceuticals Usa Inc5 April 20241
Somerset Therapeutics Llc9 October 20241
Acella Pharmaceuticals Llc14 November 20241

2 more makers are listed in the data.

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Oral

Four or more generic makers listed

Brand listed as marketed: Vimpat. 10 generic makers with 10 generic products listed as marketed; the first generic approval is dated 19 May 2022.

20102015202020252030010brand 2010Alkem Laboratories Ltd, first approval 19 May 2022Hetero Labs Ltd Unit Iii, first approval 31 May 2022Novitium Pharma Llc, first approval 26 August 2022Pharmazone, first approval 6 February 2023Msn Laboratories Private Ltd, first approval 22 December 2023Aurobindo Pharma Ltd, first approval 24 January 2024Chartwell Rx Sciences Llc, first approval 15 May 2024Ajenat Pharmaceuticals Llc, first approval 26 June 2025Regcon Holdings Llc, first approval 29 January 2026Product Development Partners Llc, first approval 15 June 2026data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Alkem Laboratories Ltd19 May 20221
Hetero Labs Ltd Unit Iii31 May 20221
Novitium Pharma Llc26 August 20221
Pharmazone6 February 20231
Msn Laboratories Private Ltd22 December 20231
Aurobindo Pharma Ltd24 January 20241
Chartwell Rx Sciences Llc15 May 20241
Ajenat Pharmaceuticals Llc26 June 20251
Regcon Holdings Llc29 January 20261
Product Development Partners Llc15 June 20261

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Capsule, Extended Release, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Motpoly Xr. No generic is listed as marketed.

2020202520302035204001brand 2023data datePatent 11337943 listed to expire 5 June 2040Patent 12042474 listed to expire 5 June 2040Patent 11883374 listed to expire 5 June 2040
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 5 June 2040Patent 11337943 drug product
  • 5 June 2040Patent 12042474 drug product
  • 5 June 2040Patent 11883374 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.